Electrophysiological analysis reveals ivabradine's role in atrial fibrillation, highlighting its impact on calcium handling and afterdepolarizations.
Abstract ObjectiveThe present paper is to determine the effects and underlying mechanisms of ivabradine (IVA) on atrial fibrillation (AF).MethodsElectrophysiological changes were determined using Langendorff-perfused hearts and patch-clamp techniques. Parameters of Ca²⁺ handling were evaluated by using calcium imaging and western blotting.ResultsIVA (0.1–10 µM) slowed HR in a concentration-dependent manner in isolated hearts of rabbit. IVA induced atrial arrhythmias in 26.1% and 76.9% of hearts paced at a basic cycle length of 350 and 570 ms, respectively. In hearts pretreated with either acetylcholine (ACh) or anemone toxin-II (ATX-II) which caused no inducible atrial arrhythmias, adding to IVA administration caused atrial arrhythmias in 61.9% (13/21) and 44.4% (8/18) of hearts, respectively. In atrial myocytes, IVA induced DADs by 41.7%, 62.5% and 50.0%, respectively, in the absence and presence of either ACh or ATX-II. IVA increased the frequency, amplitude and full width at half-maximum (FWHM) of Ca²⁺ sparks and decreased Ca²⁺ transport in association with increased protein expression of RyR2 and NCX1 and decreased SERCA2.ConclusionIVA increases atrial proarrhythmic risk in hearts with a slow HR, enhanced vagal tone and increased late sodium current by inducing DADs resulting from an enhanced intracellular Ca²⁺ inhomeostasis.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: